Repare Therapeutics (NASDAQ:RPTX), Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel cancer therapies through the exploitation of synthetic lethality. Leveraging a proprietary platform that integrates functional genomics, bioinformatics and chemical biology, the company aims to identify and inhibit key targets in the DNA damage response (DDR) pathway. Its lead programs include small-molecule inhibitors designed to selectively kill tumor cells with specific genetic defects, including PARP1/2 inhibitors and next-generation DDR modulators targeting ATR, ATM and DNA-PK.
Founded in 2016 and headquartered in Montreal, Canada, Repare Therapeutics emerged from cutting-edge academic research into synthetic lethality. The company has since established a presence in the United States with a research and development office in Boston, Massachusetts, enabling close collaboration with clinical sites and regulatory agencies in North America and Europe. Repare’s global approach seeks to advance its pipeline efficiently through Phase 1 and Phase 2 studies, with a focus on solid tumors characterized by defects in DNA repair pathways.
Repare’s leadership team is led by Chief Executive Officer Eric Ostreicher, who brings experience in oncology drug development and corporate strategy. The executive team also includes seasoned industry veterans in clinical operations, regulatory affairs and commercial planning. Repare’s board of directors comprises experts in biotechnology finance, pharmaceutical development and translational oncology, guiding the company through its transition from discovery-stage research to clinical execution.
Through partnerships and collaborations with academic institutions and biopharmaceutical companies, Repare Therapeutics continues to expand its DDR-focused pipeline. The company’s strategic alliances aim to broaden the application of its synthetic lethality platform across multiple tumor types and to explore combination regimens with existing oncology therapies. With a commitment to precision medicine, Repare is positioned to bring innovative, targeted treatments to patients with genetically defined cancers.
